Jade Biosciences (JBIO) Invested Capital (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Invested Capital data on file, last reported at $296.5 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 455.0% year-over-year to $296.5 million; the trailing twelve-month figure through Mar 2026 stood at $296.5 million (up 455.0% YoY), and the FY2025 full-year result was $332.5 million, up 810.52% from the prior year.
• Invested Capital for Q1 2026 stood at $296.5 million, down from $332.5 million in the prior quarter.
• Across five years, Invested Capital topped out at $332.5 million in Q4 2025 and bottomed at -$83.5 million in Q1 2025.
• The 5-year median for Invested Capital is $126.7 million (2022), against an average of $118.9 million.
• Peak annual rise in Invested Capital reached 34320.03% in 2025, while the deepest fall reached 191.87% in 2025.
• A 5-year view of Invested Capital shows it stood at $126.7 million in 2022, then dropped by 13.64% to $109.5 million in 2023, then sank by 142.76% to -$46.8 million in 2024, then jumped by 810.52% to $332.5 million in 2025, then declined by 10.84% to $296.5 million in 2026.
• The last three Invested Capital figures came in at $296.5 million (Q1 2026), $332.5 million (Q4 2025), and $179.3 million (Q3 2025), per Business Quant data.

Peer Comparison